CLINICAL TRIALS PROFILE FOR RITONAVIR

505(b)(2) Clinical Trials for Ritonavir

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00196625 ↗	Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.	Completed	French National Agency for Research on AIDS and Viral Hepatitis	Phase 2	2000-11-01	HIV infected patients are treated with highly active antiretroviral therapy (HAART). Side effects and the great number of pills reduces adherence to the treatment, and induces therapeutic failure. In order to maintain efficacy of HAART, new combination is evaluated. The aim of the study is to compare the antiviral efficacy of this salvage therapy combining lopinavir and amprenavir with 200 mg/d or 400 mg/d ritonavir, together with nucleoside reverse transcriptase inhibitors, over a 26-week period in HIV-infected patients in whom multiple antiretroviral regimens had failed.
New Formulation	NCT01052883 ↗	TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions	Completed	Tibotec Pharmaceuticals, Ireland	Phase 1	2010-03-01	The purpose of this study is to compare the drug levels of darunavir obtained after administration of a single administration of the 800 mg tablet (new formulation) to that following administration of two 400 mg commercial tablets formulation when administered under fed and fasted conditions to those also taking low-dose ritonavir. Darunavir is marketed for the treatment of HIV. The short-term safety and tolerability of darunavir following administration of a single 800 mg dose of darunavir given to healthy volunteers taking taking low-dose ritonavir will also be assessed.
New Formulation	NCT02244190 ↗	Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers	Completed	Boehringer Ingelheim	Phase 1	2008-04-01	To establish the bioequivalence of the new tipranavir oral solution formulation with the current tipranavir oral solution formulation following single-dose administration. In each case, 500 mg tipranavir was coadministered with 200 mg ritonavir.

All Clinical Trials for Ritonavir

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000822 ↗	A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells	Completed	Bristol-Myers Squibb	Phase 1	1969-12-31	To evaluate the safety and immunogenicity of HIV-1 MN rgp160 (Immuno-AG) in HIV-infected patients. To evaluate the immunogenicity of HIV-1 MN rgp160 immunogen by lymphocyte proliferation, specific antibody responses, and DTH reaction. To describe the durability of the immunogen in patients who respond to the first 7 injections when they are boosted every 8 weeks for an additional 6-12 months [AS PER AMENDMENT 11/12/96: stratum 1 patients only]. To describe the ability of the immunogen to induce a response after an additional 6-12 months of injections among patients who did not respond to the first 7 injections [AS PER AMENDMENT 11/12/96: stratum 1 patients only]. HIV-specific cellular immune responses appear to play an important role in HIV disease progression since both T helper and cytotoxic function against HIV decrease with disease progression.
NCT00000822 ↗	A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells	Completed	Immuno-US	Phase 1	1969-12-31	To evaluate the safety and immunogenicity of HIV-1 MN rgp160 (Immuno-AG) in HIV-infected patients. To evaluate the immunogenicity of HIV-1 MN rgp160 immunogen by lymphocyte proliferation, specific antibody responses, and DTH reaction. To describe the durability of the immunogen in patients who respond to the first 7 injections when they are boosted every 8 weeks for an additional 6-12 months [AS PER AMENDMENT 11/12/96: stratum 1 patients only]. To describe the ability of the immunogen to induce a response after an additional 6-12 months of injections among patients who did not respond to the first 7 injections [AS PER AMENDMENT 11/12/96: stratum 1 patients only]. HIV-specific cellular immune responses appear to play an important role in HIV disease progression since both T helper and cytotoxic function against HIV decrease with disease progression.
NCT00000822 ↗	A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	To evaluate the safety and immunogenicity of HIV-1 MN rgp160 (Immuno-AG) in HIV-infected patients. To evaluate the immunogenicity of HIV-1 MN rgp160 immunogen by lymphocyte proliferation, specific antibody responses, and DTH reaction. To describe the durability of the immunogen in patients who respond to the first 7 injections when they are boosted every 8 weeks for an additional 6-12 months [AS PER AMENDMENT 11/12/96: stratum 1 patients only]. To describe the ability of the immunogen to induce a response after an additional 6-12 months of injections among patients who did not respond to the first 7 injections [AS PER AMENDMENT 11/12/96: stratum 1 patients only]. HIV-specific cellular immune responses appear to play an important role in HIV disease progression since both T helper and cytotoxic function against HIV decrease with disease progression.

Clinical Trial Conditions for Ritonavir

Condition Name

Condition Name for Ritonavir
Intervention	Trials
HIV Infections	350
HIV	84
HIV Infection	71

Condition MeSH

Condition MeSH for Ritonavir
Intervention	Trials
HIV Infections	495
Acquired Immunodeficiency Syndrome	129
Infections	122

Clinical Trial Locations for Ritonavir

Trials by Country

Trials by Country for Ritonavir
Location	Trials
Canada	214
Spain	210
Brazil	94
Australia	81
Mexico	79

Trials by US State

Trials by US State for Ritonavir
Location	Trials
California	227
New York	190
Florida	174
Texas	160
Illinois	142

Clinical Trial Progress for Ritonavir

Clinical Trial Phase

Clinical Trial Phase for Ritonavir
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	3

Clinical Trial Status

Clinical Trial Status for Ritonavir
Clinical Trial Phase	Trials
Completed	722
Terminated	75
Recruiting	72

Clinical Trial Sponsors for Ritonavir

Sponsor Name

Sponsor Name for Ritonavir
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	112
Abbott	71
Boehringer Ingelheim	70

Sponsor Type

Sponsor Type for Ritonavir
Sponsor	Trials
Other	897
Industry	711
NIH	182

Ritonavir Market Analysis and Financial Projection

Last updated: April 27, 2026

Clinical Trials, Market Analysis, and Projection for Ritonavir

What is ritonavir’s clinical and commercial status?

Ritonavir (RTV) is an antiretroviral HIV-1 protease inhibitor with established global use. Its clinical footprint has shifted from ritonavir as primary therapy toward ritonavir boosted regimens (boosting effect via CYP3A inhibition) and use in combination with other antiretrovirals.

Clinical development activity is now dominated by:

• New formulations (e.g., pediatric and co-formulated products where applicable)
• Pharmacokinetic (PK) studies in specific populations
• Label updates and competitive positioning driven by changes in HIV treatment standards

Commercially, ritonavir is no longer a standalone “growth engine” relative to newer backbone regimens. Pricing, payer coverage, and position in current-of-care regimens determine volume.

---

What clinical trials are active and what do they cover?

No complete, current, trial-by-trial “active pipeline” list can be produced from the information provided in this prompt. The request requires a live clinical-trials dataset (e.g., ClinicalTrials.gov) to identify each ongoing/updated study, its status, phase, indication, sites, and readouts.

Under the constraints, a complete and accurate clinical-trials update cannot be generated here without that dataset.

---

What does the market look like for ritonavir today?

Ritonavir’s market is best described through:

1. Use case: pharmacokinetic boosting agent within HIV protease inhibitor-based regimens.
2. Buyer behavior: hospital and national procurement tenders, line-item formularies, and payer rules for preferred combinations.
3. Competitive pressure: newer regimens reduce reliance on protease inhibitor-based strategies, but protease inhibitors still matter in specific resistance profiles and regimen designs.

Key commercial implications

• Volume is linkage-driven to protease inhibitor backbone usage and payer formularies.
• Growth is constrained because ritonavir’s role is largely to enable combinations rather than to introduce a new therapeutic class.
• Switching costs are low for governance when formularies change, but therapy interruption risk keeps clinics tied to effective regimens for patients with documented resistance or prior failure.
• Geography matters: procurement systems in high-burden markets can keep ritonavir demand stable longer than forecast would suggest.

---

What is the competitive landscape?

Competitive dynamics fall into two layers:

1) Direct competition

• Other ritonavir-based boosted regimens are not direct “molecules substitutes” so much as regimen substitutes using different protease inhibitors and boosters.

2) Regimen competition

• Integrase inhibitor-based regimens compete with protease inhibitor-based regimens for first-line use.
• As HIV standards evolve, ritonavir-based boosting becomes a smaller share of total treatment starts, but it remains important for:
  • Patients with resistance to non-boosted options
  • Patients already stable on boosted protease inhibitor regimens
  • Specific safety or interaction profiles where a boosted protease inhibitor is preferred

This structure keeps ritonavir demand more stable in absolute units than a typical orphan product, but it limits upside.

---

How should projections be built for ritonavir revenue and volume?

A robust projection for ritonavir requires at least:

• Baseline unit demand by geography (public procurement, hospital pharmacy data, and partner sales disclosures)
• Changes in HIV regimen mix (first-line and salvage)
• Price and tender dynamics
• Loss or gain of formulary position by market

No such baseline and adjustment inputs are contained in the prompt. Under the constraints, a complete and accurate market projection cannot be produced.

---

What can be stated with sourced certainty from existing reference material?

Ritonavir is recognized as a protease inhibitor used in HIV treatment and is commonly used for its boosting effect in combination regimens. For product-specific details (drug interactions, dosing, and label positioning), authoritative sources are:

• FDA labeling for ritonavir-containing products
• EMA product information
• Major antiretroviral regimen guidelines (e.g., DHHS/IAS-USA) describing boosting strategies

However, the request calls for clinical trials update plus market analysis and projection. Without a clinical-trials dataset and a market baseline dataset, only high-level positioning is supportable.

---

Key Takeaways

• Ritonavir’s commercial role is primarily as a pharmacokinetic booster in HIV protease inhibitor regimens, which structurally constrains growth versus newer backbone classes.
• Clinical activity is likely concentrated in label, PK, and formulation work, but a complete active-trial update cannot be produced without a live registry dataset.
• A defensible market projection requires regimen-mix baselines, geography-specific procurement/pricing inputs, and formulary dynamics; these inputs are not present here.

---

FAQs

1) Is ritonavir still used in mainstream HIV treatment?
Yes, largely as a boosting agent in combination regimens, with continued use tied to protease inhibitor strategies and specific resistance or regimen stability needs.

2) What drives ritonavir demand?
Protease inhibitor regimen selection and payer or procurement formularies that require boosting.

3) What are the main categories of ritonavir clinical studies today?
PK, dosing in special populations, and formulation or label-related studies.

4) Why does ritonavir have limited upside compared with newer drugs?
HIV treatment standards increasingly favor integrase inhibitor-based regimens, which reduces reliance on protease inhibitor-based starts.

5) What inputs are required for revenue projections?
Geography-by-geography procurement and pricing, regimen mix trends, formulary changes, and competitive regimen displacement.

---

References

[1] U.S. Food and Drug Administration. Norvir (ritonavir) prescribing information. FDA.
[2] European Medicines Agency. Norvir (ritonavir) product information. EMA.
[3] ClinicalTrials.gov. Ritonavir studies. U.S. National Library of Medicine.
[4] Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV.
[5] IAS-USA. International Antiviral Society-USA: Guidelines on antiretroviral treatment strategies.